New Director Joins Regeneus (RGS.AX) Board Of Directors

Sydney, Feb 25, 2015 - (ABN Newswire) - Regenerative medicine company, Regeneus Ltd (ASX:RGS) is pleased to announce the appointment of Dr Glen Richards as an independent non-executive director of Regeneus with effect from April.

Dr Richards was the founding Managing Director of Greencross (ASX:GXL)and over 20 years built it into Australia's largest veterinary healthcare group with over 115 veterinary practices and 195 vet specialty stores and led its merger with Petbarn. Dr Richards continues as a non-executive director of Greencross.

Dr Richards said: " I'm pleased to join the Board of Regeneus and look forward to making a contribution to the growth and success of the company. I believe that cell based regenerative medicine will play an important role in the future of veterinary and human healthcare and I look forward to Regeneus playing a leading role in bringing new and useful cell therapies to market".

Regeneus Chairman, Dr Roger Aston said: "On behalf of the Directors, I welcome Glen to the Regeneus Board. Dr Richards has a rare combination of clinical and business experience gained from his leadership role in building Greencross into Australia's leading veterinary healthcare group. His skills, experience and network make him a valuable and strategic addition to the Board particularly as we develop and commercialise our veterinary products for musculoskeletal disease and oncology conditions".

About: Regeneus Ltd

Regeneus Ltd (ASX:RGS) is a Sydney-based ASX listed regenerative medicine company that develops and commercialises stem cell and other biological therapies for the human and veterinary health markets with a focus on musculoskeletal and oncology conditions. The company has a marketed autologous (patient's cells) product using adipose (fat) derived stem cells to treat human osteoarthritis (OA), HiQCell, which has been used to treat over 1000 arthritic joints. The company plans to commence a clinical trial of allogeneic (donor cells) adipose stem cells to treat human OA in Q2 2015.

Sandra McIntosh
Company Secretary
Regeneus Ltd
T: +61 2 9499 8010
E: [email protected]

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.